PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - vitallaw.com
A federal court in Tennessee rejected AbbVie's challenge to the state's contract pharmacy law, upholding the law's requirements for drug manufacturers to distribute to contract pharmacies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug manufacturers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that distribute prescription drugs in Tennessee. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided; compliance should be immediate.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The court upheld Tennessee's contract pharmacy law, meaning manufacturers must comply with state requirements for distributing drugs through contract pharmacies.
Who it affects
Branded drug manufacturers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that distribute prescription drugs in Tennessee.
What you must do
Review Tennessee's contract pharmacy law and ensure distribution agreements and practices comply with its requirements.
Deadline
No specific deadline provided; compliance should be immediate.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- WY HB0013: Ivermectin-no prescription required.